Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Columbia University Irving Medical Center

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1212
Shown on this page
12
Current sort
Recently updated
Campus scope
Columbia University Irving Medical Center, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Columbia University Irving Medical Center, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 625–636 of 1,212 matching trials with a site at Columbia University Irving Medical Center, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Not applicable Interventional Results available

Xeltis Bioabsorbable Pulmonary Valved Conduit Pivotal Study

NCT03022708
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Defect, Congenital
Interventions
Xeltis Bioabsorbable Pulmonary Valved Conduit
Device
Lead sponsor
Xeltis
Industry
Eligibility
2 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Hollywood, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

NCT06456463
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Tagraxofusp, Venetoclax, Azacitidine
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
24
States / cities
Los Angeles, California • Stanford, California • Miami, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Active, not recruiting Phase 2 Interventional Results available

Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma

NCT01979523
Site status not listed — check the official record
View directory record Official record
Conditions
Recurrent Uveal Melanoma, Stage IV Uveal Melanoma AJCC v7
Interventions
Laboratory Biomarker Analysis, Pharmacological Study, Trametinib, Uprosertib
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Active, not recruiting Not applicable Interventional

WiseApp for Spanish Speakers Living With HIV

NCT05398185
Site status not listed — check the official record
View directory record Official record
Conditions
HIV Infections, Acquired Immune Deficiency Syndrome, Sexually Transmitted Diseases, Viral
Interventions
CleverCap
Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Active, not recruiting Not applicable Interventional

Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy

NCT03487185
Site status not listed — check the official record
View directory record Official record
Conditions
Obstructive Sleep Apnea of Adult, Preeclampsia, Obstetrical Complications
Interventions
Continuous Positive Airway Pressure, Sleep Advice Control
Device · Other
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Recruiting Phase 2 Interventional

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

NCT06809140
Status at this site: Recruiting
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Recruiting Phase 1Phase 2 Interventional

A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

NCT05788536
Status at this site: Recruiting
View directory record Official record
Conditions
Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)
Interventions
DB-OTO
Genetic
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Recruiting Phase 3 Interventional

Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant

NCT05654922
Status at this site: Recruiting
View directory record Official record
Conditions
Pre-Bronchiolitis Obliterans Syndrome
Interventions
ARINA-1, Standard of care only
Drug · Other
Lead sponsor
Renovion, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Recruiting Phase 3 Interventional

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

NCT05812807
Status at this site: Recruiting
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Interventions
Pembrolizumab, Patient Observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Biological · Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
828
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 600 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Autoimmune Features of Neurodegenerative Disorders

NCT04239079
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
55 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Research On Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS)

NCT07745101
Site status not listed — check the official record
View directory record Official record
Conditions
Stillbirth
Interventions
Not listed
Lead sponsor
RTI International
Other
Eligibility
18 Years and older · Female only
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
5
States / cities
San Diego, California • New York, New York • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 5, 2026, 8:48 AM EST
Active, not recruiting Phase 3 Interventional

A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

NCT06880744
Site status not listed — check the official record
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Risankizumab, Vedolizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 80 Years
Enrollment
573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
74
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Nov 5, 2026, 8:48 AM EST

About this Columbia University Irving Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Columbia University Irving Medical Center in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.